Dr. Leen Kawas, co-founder and managing general partner at Propel Bio Partners, discusses innovations within the Alzheimer’s care space.
As 21st-century technology leads to medical breakthroughs and new drug treatments, the rising incidence of Alzheimer’s is increasingly becoming one of the biggest challenges to our society and economy. According to the Alzheimer’s Association’s 2023 figures, over six million Americans are currently impacted by this debilitating disease. By 2050, almost 13 million people are predicted to be living with Alzheimer’s.
Alzheimer’s is a disease that impacts not only the patients but caregivers, partners, children, and the whole family as a unit. Alzheimer’s is one of the most expensive diseases we are tackling. In addition to the direct cost of taking care of the patient, the indirect cost is significant and can’t be ignored.
Full story: https://disruptmagazine.com/dr-leen-kawas-highlights-alzheimers-diagnosis-and-treatment-innovations/